JIPLP: Insufficiency finally upheld as ground for invalidity of antibody claim

No items found.
​
21 October 2013
Tags
Litigation
Life
Table of contents
  • Toc Heading
  • Toc Heading

The Journal of Intellectual Property Law and Practice has published an article by partner Darren Smyth about the judgement in Eli Lilly & Company v Janssen Alzheimer Immunotherapy.

Mr Justice Arnold determines that a patent directed towards antibodies to ß-amyloid peptide, for the treatment of Alzheimer's disease, is invalid for insufficiency.

To read the JIPLP article in full, click here.

Related articles

See all articles

EIP Recognised in The Times Best Law Firms 2026
03 December 2025
EIP is proud to be featured in The Times Best Law Firms 2026, a prestigious list based on peer recommendations across the legal industry. This recognition highlights EIP’s commitment to technical excellence, client-focused service, and innovative IP strategies. From high-value patent litigation to strategic portfolio management, EIP continues to deliver results that matter for clients in technology, life sciences, and engineering. This accolade reinforces our position as a trusted leader in intellectual property law.
​
EIP Launches Tech & AI Function to Drive Innovation and Client Excellence
06 November 2025
When it comes to technology, EIP has always been ahead of the curve; we are proud to announce the evolution of our IT department into a dedicated Tech & AI function, marking a bold step towards...
​
EIP shortlisted for The British Legal Awards 2025
26 September 2025
We are proud to share that we've been shortlisted for The British Legal Awards 2025 in the newly introduced category: ‘IP Team of the Year'! A special shout-out to our fantastic Litigation team,...
​